EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
Hemogenyx Pharma Plc (AIM:HEMO) HEMO-CAR-T 3rd Process Qualification Run Completed
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of
Omega Diagnostics Gp (AIM:ODX) Trading update
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, provides a trading update which reflects lower than expected revenue,
hVIVO PLC (AIM:HVO) EUR3.2m Venn contract with global pharma client
€3.2m contract for Venn Life Sciences with global pharmaceutical client
Avacta Group PLC (AIM:AVCT) Successful Completion of Fourth Dose Escalation
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Poolbeg Pharma PLC (AIM:POLB) Strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
The Essential Investing Strategy Review For 2023, HARL, PREM, AVCT, & BOIL
Buying lottery tickets on the FTSE AIM can be very rewarding, but only for investors who have already properly diversified.
ValiRx PLC (AIM:VAL) Launch of Broker Offer to raise a maximum of £500,000
Launch of Broker Offer to raise a maximum of £500,000
Braveheart Inv Group (AIM:BRH) Operational update
Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
Local health officials state that Covid has infected 90% of Chinese province residents
According to data from central Henan’s health commission, 88 million people may have been infected with the virus.
Hemogenyx Pharma Plc (LON:HEMO) Single CBR Can Treat Multiple Viruses
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to